Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Dermatology | Endocrinology | Family Medicine | Geriatrics | Gastroenterology | Gynecology | Infections | AIDS | Internal Medicine | Allergy | Critical Care | Emergency Medicine | Nephrology | Neurology | Nursing | Oncology | Ophthalmology | Orthopedics | ENT | Pathology | Pediatrics | Pharmacy | Psychiatry | Pulmonology | Radiology | Rheumatology | Surgery | Anesthesiology & Pain | Urology | Institutional

Back to Journal Articles

Head of National Cancer Institute Named Acting FDA Commissioner

Last Updated: March 13, 2019.

The U.S. Food and Drug Administration will temporarily be overseen by the head of the National Cancer Institute when FDA Commissioner Scott Gottlieb, M.D., leaves the post next month.

WEDNESDAY, March 13, 2019 (HealthDay News) -- The U.S. Food and Drug Administration will temporarily be overseen by the head of the National Cancer Institute when FDA Commissioner Scott Gottlieb, M.D., leaves the post next month.

The appointment of Ned Sharpless, M.D., was announced Tuesday, a week after Gottlieb, who was in the position for two years, said he would step down in April. He has said he wants to spend more time with his family, the Associated Press reported.

Sharpless, who has led the National Cancer Institute since October 2017, is one of several government officials believed to be in the running to become the next FDA commissioner.

A candidate for the position is nominated by the president and must be confirmed by the Senate.

AP News Article


Previous: Short Regimen Noninferior for Rifampin-Resistant Tuberculosis Next: Mumps Causes Quarantine of Over 2,200 Immigrant Detainees

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: